Editas Medicine (EDIT) Short-term Investments (2017 - 2025)

Editas Medicine (EDIT) has reported Short-term Investments for 9 consecutive years, with $40.0 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Short-term Investments fell 81.39% year-over-year to $40.0 million; the TTM figure through Jun 2025 stood at $40.0 million (down 81.39% YoY), while the FY2024 annual figure was $138.4 million, down 30.63% from the prior year.
• Short-term Investments slipped to $40.0 million in Q2 2025 per EDIT's latest filing, from $82.3 million in the prior quarter.
• Across five years, Short-term Investments topped out at $298.0 million in Q3 2021 and bottomed at $40.0 million in Q2 2025.
• Historically, Short-term Investments has averaged $213.8 million across 5 years, with a median of $212.9 million in 2023.
• Annual changes were most pronounced in 2021 — Short-term Investments surged 141.56% — and 2025, when it slumped 81.39%.
• Editas Medicine's Short-term Investments stood at $296.3 million in 2021, then sank by 31.58% to $202.8 million in 2022, then fell by 1.62% to $199.5 million in 2023, then slumped by 30.63% to $138.4 million in 2024, then tumbled by 71.12% to $40.0 million in 2025.
• Business Quant data shows EDIT's Short-term Investments at $40.0 million in Q2 2025, $82.3 million in Q1 2025, and $138.4 million in Q4 2024.